Want to see MAZE full AI Analyst Report?
Top Page
Maze Therapeutics, Inc.
(NASDAQ:MAZE)
Select Model
Select Model
Rating:45Neutral
Price Target:
$27.00
▼(-2.46% Downside)
Action:Reiterated
Date:08/18/26
MAZE’s score is weighed down primarily by weak financial performance—large TTM net losses and significant free cash flow burn—despite a comparatively strong equity base and low leverage. Technicals are also soft with the stock well below its 200-day average and negative MACD, while valuation metrics are limited by negative earnings and no dividend yield data.
Positive Factors
Strong Equity Base
The sizable equity base and low leverage provide financial flexibility for continued clinical development. This capital cushion can help Maze fund research programs and manage volatility without relying immediately on substantial additional borrowing.
Negative Factors
Large Ongoing Losses
The large loss relative to current revenue shows that operating expenses materially exceed the company’s present commercial or collaboration income. Unless clinical progress translates into partnerships, approvals, or product revenue, profitability remains a distant and uncertain objective.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Equity Base
The sizable equity base and low leverage provide financial flexibility for continued clinical development. This capital cushion can help Maze fund research programs and manage volatility without relying immediately on substantial additional borrowing.
Read all positive factors
Maze Therapeutics, Inc. (MAZE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.62B
Dividend YieldN/A
Average Volume (3M)698.25K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue Growth700.00%
EPS Growth-50.45%
CountryUS
Employees141
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.74
Shares Outstanding55,549,168
10 Day Avg. Volume397,036
30 Day Avg. Volume698,254
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$66.25Price Target Upside139.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.76
Revenue Forecast (FY)$22.00M
Maze Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhi...
How the Company Makes Money
null...
Maze Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.00M | 0.00 | 167.50M | 0.00 | 0.00 |
| Gross Profit | 19.06M | -2.40M | 167.50M | 0.00 | 0.00 |
| EBITDA | -130.28M | -128.72M | 56.70M | -96.33M | -111.12M |
| Net Income | -133.59M | -131.12M | 52.23M | -100.42M | -114.94M |
Balance Sheet | |||||
| Total Assets | 531.63M | 397.13M | 240.54M | 71.50M | 149.96M |
| Cash, Cash Equivalents and Short-Term Investments | 411.09M | 341.92M | 196.81M | 29.16M | 99.92M |
| Total Debt | 60.42M | 23.31M | 26.63M | 49.62M | 32.05M |
| Total Liabilities | 78.50M | 42.16M | 43.64M | 61.45M | 48.51M |
| Stockholders Equity | 453.12M | 354.97M | 196.90M | 10.05M | 101.44M |
Cash Flow | |||||
| Free Cash Flow | -106.84M | -112.73M | 74.81M | -87.27M | -101.17M |
| Operating Cash Flow | -106.54M | -111.94M | 75.95M | -86.83M | -99.20M |
| Investing Cash Flow | -292.50M | -170.96M | -1.15M | -441.00K | -3.17M |
| Financing Cash Flow | 337.14M | 275.34M | 92.85M | 16.39M | 1.73M |
Maze Therapeutics, Inc. Technical Analysis
Positive
27.68
Price Trends
27.53
Positive
21.03
Positive
Market Momentum
1.29
Positive
60.57
Neutral
78.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MAZE, the sentiment is Positive. The current price of 27.68 is below the 20-day moving average (MA) of 31.15, above the 50-day MA of 27.53, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 1.29 indicates Positive momentum. The RSI at 60.57 is Neutral, neither overbought nor oversold. The STOCH value of 78.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MAZE.
Maze Therapeutics, Inc. Risk Analysis
Maze Therapeutics, Inc. disclosed 84 risk factors in its most recent earnings report. Maze Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
Maze Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $1.96B | -0.26 | -82.56% | ― | ― | -850.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.63B | -3.95 | -57.79% | ― | 12.58% | 28.42% | |
51 Neutral | $1.66B | -3.37 | -50.41% | ― | -15.08% | 41.98% | |
49 Neutral | $2.06B | -16.01 | -26.51% | ― | ― | ― | |
46 Neutral | $439.73M | -1.54 | -60.21% | ― | -51.54% | 7.05% | |
45 Neutral | $1.62B | -10.86 | -34.94% | ― | 700.00% | -50.45% |
* Healthcare Sector Average
MAZE
Maze Therapeutics, Inc.
28.93
15.70
118.67%
NTLA
Intellia Therapeutics
12.44
2.31
22.86%
DMRA
Damora Therapeutics
30.31
26.93
796.75%
RXRX
Recursion Pharmaceuticals
3.34
-1.44
-30.13%
DNA
Ginkgo Bioworks Holdings
6.96
-4.80
-40.82%
GENB
Generate Biomedicines, Inc.
15.99
3.34
26.40%
Maze Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board Changes
Maze Therapeutics Strengthens Board with New Director Appointments
Positive
Aug 17, 2026
On August 13, 2026, Maze Therapeutics appointed Paula A. Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its board of directors, expanding governance with deep clinical, academic and biopharmaceutical leadership.
Johnson joins as...
Executive/Board ChangesShareholder Meetings
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
Positive
Jun 10, 2026
On June 8, 2026, Maze Therapeutics, Inc. held its 2026 annual meeting of stockholders with 44,660,029 shares of common stock represented, or about 89.75% of shares entitled to vote, establishing a quorum for business. Stockholders voted on the ele...
Executive/Board Changes
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change
Neutral
May 22, 2026
On May 18, 2026, Maze Therapeutics, Inc. announced that Senior Vice President of Finance Amy Bachrodt had submitted her resignation, effective June 1, 2026, noting that her departure did not stem from any disagreement over the company’s oper...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.